Mark T Hegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mark T Hegel has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Ryan
School of Optometry and Vision Sciences, Cardiff University, Cardiff, UK
1 shared publication - Catey Bunce
Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
1 shared publication - Claire Nollett
Centre for Vision Services Research, Cardiff University, Cardiff, UK
1 shared publication - Daniel J. Smith
Edinburgh Scotland The University of Edinburgh Division of Psychiatry
1 shared publication - Julia Shearn
School of Optometry and Vision Sciences, Cardiff University, Cardiff, CF24 4LU, UK
1 shared publication - M. R. Stanford
St. Thomas Hospital
1 shared publication
Latest Publications
- Open Access
- 6 June 2012
- Published by Springer Nature in BMC Psychiatry
- Vol. 12 (1) , 57
The Depression in Visual Impairment Trial (DEPVIT): trial design and protocol
The prevalence of depression in people with a visual disability is high but screening for depression and referral for treatment is not yet an integral part of visual rehabilitation service provision. One reason for this may be that there is no good evidence about the effectiveness of treatments in this patient group. This study is the first to evaluate the effect of depression treatments on people with a visual impairment and co morbid depression. The study is an exploratory, multicentre, individually randomised waiting list controlled trial. Participants will be randomised to receive Problem Solving Therapy (PST), a ‘referral to the GP’ requesting treatment according to the NICE’s ‘stepped care’ recommendations or the waiting list arm of the trial. The primary outcome measure is change (from randomisation) in depressive symptoms as measured by the Beck’s Depression Inventory (BDI-II) at 6 months. Secondary outcomes include change in depressive symptoms at 3 months, change in visual function as measured with the near vision subscale of the VFQ-48 and 7 item NEI-VFQ at 3 and 6 months, change in generic health related quality of life (EQ5D), the costs associated with PST, estimates of incremental cost effectiveness, and recruitment rate estimation. Depression is prevalent in people with disabling visual impairment. This exploratory study will establish depression screening and referral for treatment in visual rehabilitation clinics in the UK. It will be the first to explore the efficacy of PST and the effectiveness of NICE’s ‘stepped care’ approach to the treatment of depression in people with a visual impairment. ISRCTN46824140
- 6 June 2012
- Published by Springer Nature in BMC Psychiatry
- Vol. 12 (1) , 57
Open AccessThe Depression in Visual Impairment Trial (DEPVIT): trial design and protocol
The prevalence of depression in people with a visual disability is high but screening for depression and referral for treatment is not yet an integral part of visual rehabilitation service provision. One reason for this may be that there is no good evidence about the effectiveness of treatments in this patient group. This study is the first to evaluate the effect of depression treatments on people with a visual impairment and co morbid depression. The study is an exploratory, multicentre, individually randomised waiting list controlled trial. Participants will be randomised to receive Problem Solving Therapy (PST), a ‘referral to the GP’ requesting treatment according to the NICE’s ‘stepped care’ recommendations or the waiting list arm of the trial. The primary outcome measure is change (from randomisation) in depressive symptoms as measured by the Beck’s Depression Inventory (BDI-II) at 6 months. Secondary outcomes include change in depressive symptoms at 3 months, change in visual function as measured with the near vision subscale of the VFQ-48 and 7 item NEI-VFQ at 3 and 6 months, change in generic health related quality of life (EQ5D), the costs associated with PST, estimates of incremental cost effectiveness, and recruitment rate estimation. Depression is prevalent in people with disabling visual impairment. This exploratory study will establish depression screening and referral for treatment in visual rehabilitation clinics in the UK. It will be the first to explore the efficacy of PST and the effectiveness of NICE’s ‘stepped care’ approach to the treatment of depression in people with a visual impairment. ISRCTN46824140